 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
ZIPRASIDONE: A NEW
ATYPICAL ANTIPSYCHOTIC AGENT
Bong G Yu and Jacqueline
P Merrick
To request full article click here.
OBJECTIVE: To evaluate ziprasidone for the treatment of schizophrenia with respect to its pharmacology, pharmacokinetics, adverse effect profiles, and drug interaction potential.
DATA SOURCE: A MEDLINE search (1966–May 2001) was conducted for primary and secondary sources focusing on atypical antipsychotics and ziprasidone.
STUDY SELECTION: All of the articles identified from the data source were evaluated and all information deeme
DATA SYNTHESIS: Like other atypical antipsychotics, ziprasidone works by blocking serotonin and dopamine receptors in the mesolimbic and mesocortical regions of the brain. Ziprasidone is equally effective as haloperidol in treating schizophrenia or schizoaffective disorders. A proposed advantage of ziprasidone over other atypical antipsychotics is lower incidence of weight gain. As with a number of other psychotropic agents such as thioridazine, prolongation of the QTc interval should be monitored for patients receiving ziprasidone.
CONCLUSIONS: Based on adverse effect profiles and relatively fewer drug interactions, ziprasidone is recommended for patients who are elderly and taking multiple medications.
J Pharm Technol 2001;17:257-63.
ACPE Universal Program Number: 407-000-01-054-H01
To order the complete CE article click here.
To request full article click here.
|
|
|
||
|
